Five Eleven Pharma
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Five Eleven Pharma sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Five Eleven Pharma: 6 sponsored US clinical trials, 1 recruiting.
Five Eleven Pharma sponsors 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 4 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 3 trials.
Upper-quartile sponsor footprint
Five Eleven Pharma sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
PSMA-PET to Guide Prostatectomy
NCT05381103
Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer
NCT03444844
Initial Investigation of [18F]P17-059 in Parkinson's Disease Patients and Healthy Volunteers
NCT03903549
Initial Investigation of [18F]P16-129 in Alzheimer's Disease Patients and Healthy Volunteers
NCT03902548
Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer
NCT03073395
Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041
NCT02826382
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 1 |
Therapeutic Areas
What is open in the Five Eleven Pharma pipeline
1 recruiting of 6 indexed (17% open); 4 completed (67%).
Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (3 trials), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Five Eleven Pharma: open-pipeline peers nationwide
Peers matched on 6 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Five Eleven Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Adagene · 17% recruiting · 6 trials
- Agendia · 17% recruiting · 6 trials
- Akamis Bio · 17% recruiting · 6 trials
- Angiodynamics · 17% recruiting · 12 trials
Related
What to do with this Five Eleven Pharma page
6 registered trials is a research-attention snapshot, not an endorsement of Five Eleven Pharma or any single study.
- 1 of Five Eleven Pharma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition Five Eleven Pharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Five Eleven Pharma pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.